Skip to Content Subscribe Our Offers My Account Manage My Subscriptions FAQ Newsletters Canada Canadian True Crime Canadian Politics Health World Israel & Middle East Financial Post NP Comment Longreads Puzzmo Diversions Comics NP News Quiz New York Times Crossword Horoscopes Life Eating & Drinking Style Sponsored Play for Ontario Travel Travel Canada Travel USA Travel International Cruises Travel Essentials Culture Books Celebrity Movies Music Theatre Television Business Essentials Advice Lives Told Tails Told Shopping Buy Canadian Home Living Outdoor Living Tech Style & Beauty Kitchen & Dining Personal Care Entertainment & Hobbies Gift Guide Travel Guide Deals Savings National Post Store More Sports Hockey Baseball Basketball Football Soccer Golf Tennis Driving Vehicle Research Reviews News Gear Guide Obituaries Place an Obituary Place an In Memoriam Classifieds Place an Ad Celebrations Working Business Ads Archives Healthing Epaper Manage Print Subscription Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ Newsletters Canada World Financial Post NP Comment Longreads Puzzmo Diversions Life Shopping Epaper Manage Print Subscription HomeNewsCanadaGeneric Ozempic landing soon on Canadian pharmacy shelvesThe generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, ApotexLast updated 27 minutes ago You can save this article by registering for free here. Or sign-in if you have an account.Generic Ozempic will soon be on Canadian pharmcy shelves after Health Canada approved two submissions from manufacturers. Photo by INDRANIL MUKHERJEE /AFP via Getty ImagesGeneric versions of semaglutide, popularly known as Ozempic, will soon be available in Canadian pharmacies.Enjoy the latest local, national and international news.Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events.Unlimited online access to National Post.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles including the New York Times Crossword.Support local journalism.Enjoy the latest local, national and international news.Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events.Unlimited online access to National Post.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles including the New York Times Crossword.Support local journalism.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountorCanadian-based Apotex announced the launch of its generic version in mid-May. A statement from the company said that its initial inventory shipped to wholesalers and the “Apo-Semaglutide Injection will be on pharmacy shelves across Canada within the coming weeks.”The company said it will give patients and healthcare providers access to “affordable alternatives” to the brand-name versions.Get a dash of perspective along with the trending news of the day in a very readable format.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of NP Posted will soon be in your inbox.We encountered an issue signing you up. Please try againCanada became the first G7 country to approve a generic version of semaglutide on April 28, 2026, according to a statement from Health Canada. It authorized a second generic medication in early May and is reviewing seven other submissions for generic semaglutide by different companies.Health Canada’s statement noted that “many generic medications are 45 to 90 per cent cheaper than the brand name versions.”The federal department said it authorized Apotex’s submission after a “thorough review.” And like “existing products,” the generic injection is meant for the treatment of adult patients with type 2 diabetes.Supply will vary by province and by pharmacy, according to a statement from Shoppers Drug Mart.Generic semaglutide has the same active ingredient as Ozempic and is also a prescription medicine. The generic version “is expected to provide the same therapeutic effect at a lower cost for eligible patients,” said Shoppers.Semaglutide has also been available under the brand name Wegovy. Ozempic was designated by the manufacturer, Novo Nordisk, for type 2 diabetes, while Wegovy was designated for weight loss, said the Canadian Medical Association (CMA).The CMA notes in a statement on its website that health insurance coverage “looks very different for weight management,” with only a small number of private insurance plans offering “partial coverage.” Meanwhile, says the CMA, “public drug plans generally do not cover them.” TSince the original formulation can cost “several thousand dollars per year (when) insurance doesn’t cover it, many Canadians have to pay out of pocket, making it hard to afford,” said the CMA.However, once several generic versions become available, prices usually drop, says the association, providing “more affordable” access for Canadians.Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our daily newsletter, Posted, here. Join the Conversation This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.